Willy Barton / Shutterstock.com
Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline (GSK).
In an announcement yesterday, August 27, Ionis said GSK had decided to agree on licensing the programme following positive phase two results.
Chronic hepatitis B is a viral infection of the liver that can lead to significant and potentially fatal health conditions such as liver failure and liver cancer.
As part of the agreement, Ionis is eligible to receive milestone payments of up to $262 million, including a $25 million licence fee, as well as tiered royalties “in the low double digits” on net sales.
According to the press release, GSK is now responsible or all development, regulatory and commercialisation activities and costs.
Brett Monia, chief operating officer at Ionis, said the antisense technology “can potentially deliver a transformative medicine” for sufferers.
He added: "We believe GSK's expertise in infectious diseases makes them the ideal partner to help address this high unmet need."
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
GlaxoSmithKline, Ionis Pharmaceuticals, antisense, chronic hepatitis B, licensing, liver cancer, liver disease, virus